Dhanraj Sugars And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 02-11-2024
- Paid Up Capital ₹ 1.00 M
as on 02-11-2024
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 1310.00%
(FY 2023)
About Dhanraj Sugars And Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Naresh Kella, Lalit Kella, and Dhanraj Govindram serve as directors at the Company.
- CIN/LLPIN
U15432GJ2021PTC123900
- Company No.
123900
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jul 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surendra Nagar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Dhanraj Sugars And Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naresh Kella  | Director | 07-Jul-2021 | Current |
| Lalit Kella | Director | 07-Jul-2021 | Current |
| Dhanraj Govindram | Director | 07-Jul-2021 | Current |
Financial Performance and Corporate Structure Insights of Dhanraj Sugars And Pharmaceuticals.
Dhanraj Sugars And Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Dhanraj Sugars And Pharmaceuticals?
Unlock access to Dhanraj Sugars And Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Dhanraj Sugars Private LimitedActive 13 years 8 monthsNaresh Kella, Lalit Kella and 1 more are mutual person
The State Trading Corporation Of India LimitedActive 68 years 7 monthsNaresh Kella is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dhanraj Sugars And Pharmaceuticals?
Dhanraj Sugars And Pharmaceuticals has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dhanraj Sugars And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dhanraj Sugars And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
